Please tell us about your clinical experience. How many patients with ovarian cancer do you see on a yearly basis? What is the standard of care and what treatments are available for FRalpha,-high platinum-resistant ovarian cancer ?

What percent of the patients have been previously treated with Avastin, and have not responded well?

What percent of ovarian cancer is folate receptor alpha high?

Could you please discuss the results of the SORAYA study, where:-treatment with mirvetuximab achieved an ORR of 32.4% and 31.6% as assessed by a study investigator and a blinded independent central review. The median duration response was 5.9 months as of the data cut-off date. -Nearly half of responding patients have continued on therapy and the company expects the final median DOR to improve and could range from 5.7 to just above 7 months. -a 10% discontinuation rate.

How likely is this data to be replicated in a follow-up single-arm study?

Could you compare the results to $MRSN’s, with ~35% of patients having 4+ prior lines and the rest 1-3 @ ~34% ORR in napi2b high patients?

How likely would you be to prescribe mirvetuximab for your patients?